Intellect vs Superluminal Medicines

Side-by-side comparison of AI visibility scores, market position, and capabilities

Superluminal Medicines leads in AI visibility (86 vs 40)
Intellect logo

Intellect

EmergingHealthcare

Mental Health Benefits

Intellect is a mental health platform providing employer-sponsored coaching, therapy, and wellbeing programs focused on the Asia-Pacific market. HQ: Singapore.

AI VisibilityBeta
Overall Score
C40
Category Rank
#1 of 2
AI Consensus
60%
Trend
up
Per Platform
ChatGPT
32
Perplexity
45
Gemini
49

About

Intellect is a corporate mental health platform providing employers in Asia-Pacific access to mental health coaching, therapy, crisis support, and digital wellbeing programs for their employees. Founded in 2019 in Singapore by Theodoric Chew, the platform addresses the significant mental health challenges in Asian workplaces, where stigma around seeking mental health support has historically been higher than in Western markets but awareness is growing, particularly among younger workforce generations.

Full profile
Superluminal Medicines logo

Superluminal Medicines

LeaderHealthcare

General

Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.

AI VisibilityBeta
Overall Score
A86
Category Rank
#85 of 1158
AI Consensus
59%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
80
Gemini
93

About

Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.

Full profile

AI Visibility Head-to-Head

40
Overall Score
86
#1
Category Rank
#85
60
AI Consensus
59
up
Trend
stable
32
ChatGPT
83
45
Perplexity
80
49
Gemini
93
44
Claude
83
38
Grok
95

Key Details

Category
Mental Health Benefits
General
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Intellect
Mental Health Benefits

Integrations

Only Superluminal Medicines

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.